aripiprazole has been researched along with Disease Models, Animal in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (6.85) | 29.6817 |
| 2010's | 55 (75.34) | 24.3611 |
| 2020's | 13 (17.81) | 2.80 |
| Authors | Studies |
|---|---|
| Blackwell, W; Brockel, B; Campbell, JB; Rosamond, J; Steelman, G; Urbanek, RA; Wesolowski, SS; Widzowski, DV; Wu, Y; Xiong, H; Zhang, M | 1 |
| Akber Aisa, H; Chen, W; Guo, S; He, Y; Hu, T; Jiang, X; Li, J; Liu, Y; Shen, J; Wang, Y; Wang, Z; Wu, C; Xiamuxi, H; Xie, Y; Xu, M; Yang, F; Zhang, J; Zhao, Q | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Cheng, J; Fan, L; Liu, R; Tan, L; Wang, H; Wang, S; Yan, W; Yu, J | 1 |
| Choi, JY; Jeong, YJ; Ko, YG; Lee, HJ; Oh, SJ; Park, HJ; Son, Y | 1 |
| Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z | 1 |
| Dashti, S; Nahavandi, A | 1 |
| Burguière, E; Lamothe, H; Lavielle, O; Mallet, L; Mondragón-González, LS; Rebbah, S; Schreiweis, C | 1 |
| de Andrade, GM; de Barros Viana, GS; de Oliveira Ferreira, E; Lima, FAV; Neves, KRT; Pessoa Gomes, JM | 1 |
| Aboul-Fotouh, S; El-Salam, MFA; Elayat, WM; Elhossiny, RM; Habib, MZ; Hassan, GAM; Mohamad, MI; Zohny, SM | 1 |
| Kopciuch, D; Kus, K; Murawiecka, P; Nowakowska, E; Paczkowska, A; Ratajczak, P; Słodzińska, I; Zaprutko, T | 1 |
| Baldaia, MA; Barros-Santos, T; Berro, LF; Borges, ALN; Cata-Preta, EG; de Santana Santos, ACG; Frussa-Filho, R; Hollais, AW; Libarino-Santos, M; Marinho, EAV; Nunes Brandão, NR; Oliveira-Lima, AJ; Santos-Baldaia, R | 1 |
| Anjos-Santos, A; Barros-Santos, T; Berro, LF; Borges, ÁLN; Brandão, NRN; Brito, ACL; Cata-Preta, EG; Cruz, FC; Kisaki, ND; Libarino-Santos, M; Marinho, EAV; Oliveira, TS; Oliveira-Campos, D; Oliveira-Lima, AJ; Silva, AAF | 1 |
| Mesripour, A; Shahnamnia, S; Taymouri, S; Varshosaz, J | 1 |
| Kamińska, K; Lech, MA; Leśkiewicz, M; Lorenc-Koci, E; Rogóż, Z | 1 |
| Czaja, N; Kus, K; Nowakowska, E; Ratajczak, P; Zaprutko, T | 1 |
| Adham, N; Banasr, M; Duman, RS; Duric, V; Franklin, T; Gyertyán, I; Kiss, B; Lepack, A | 1 |
| Demlova, R; Drazanova, E; Horska, K; Karpisek, M; Kasparek, T; Kotolova, H; Ruda-Kucerova, J | 1 |
| Abaei, A; Boeckers, TM; Fegert, JM; Hengerer, B; Nespoli, E; Rasche, V; Rizzo, F | 1 |
| Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S | 1 |
| Amano, I; Obi, K; Takatsuru, Y | 1 |
| Demlova, R; Drazanova, E; Horska, K; Kasparek, T; Kratka, L; Ruda-Kucerova, J; Starcuk, Z | 1 |
| Kus, K; Nowakowska, E; Ratajczak, P; Skurzyńska, M | 1 |
| Arunagiri, P; Balamurugan, E; Irene, M; Saravanakumar, M | 1 |
| Hasegawa, S; Hida, H; Miyake, Y; Mouri, A; Nabeshima, T; Noda, Y; Ozaki, N; Yamada, K; Yoshimi, A | 1 |
| Bastos, JR; de Miranda, AS; Machado, FS; Marciano Vieira, ÉL; Moreira, FA; Perico, KM; Teixeira, AL | 1 |
| Lorenc-Koci, E; Rogóż, Z; Wąsik, A | 1 |
| Aguiar, DC; Almeida-Santos, AF; Duarte, IDG; Ferreira, RCM; Moreira, FA; Romero, TRL | 1 |
| Gill, KM; Grace, AA; Sonnenschein, SF | 1 |
| Chang, CC; Chang, HA; Chen, TY; Lin, CC; Liu, YP; Tai, YM; Tung, CS; Wan, FJ | 1 |
| Lin, JR; Nakagawasai, O; Nemoto, W; Odaira, T; Onogi, H; Sakuma, W; Srivastava, LK; Takahashi, K; Tan-No, K | 1 |
| Heo, HJ; Hong, KW; Kim, CD; Kim, HY; Lee, WS; Lee, YS; Park, SY; Shin, HK | 1 |
| Erdur, B; Ozen, M; Sabirli, R; Sarohan, A; Seyit, M; Turkcuer, I; Yilmaz, A | 1 |
| Hirakawa, M; Kunisawa, K; Libo, Z; Lu, Q; Mori, Y; Mouri, A; Nabeshima, T; Saito, K; Teshigawara, T; Yamamoto, Y; Yang, Y | 1 |
| Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R | 1 |
| Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Diberto, JF; Fish, EW; Krouse, MC; Malanga, CJ; Robinson, JE; Stringfield, SJ | 1 |
| Bleickardt, CJ; Hodgson, RA; Hunter, JC; Jones, NT; Kazdoba, TM | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Santos, R; Wuo-Silva, R | 1 |
| Hasebe, S; Kawamoto, N; Kikuta, M; Ogita, K; Shiba, T; Shuto, M; Yamaguchi, T; Yoneyama, M | 1 |
| Arunagiri, P; Balamurugan, E; Rajeshwaran, K; Shanthakumar, J; Tamilselvan, T | 1 |
| Adham, N; Gruca, P; Gyertyán, I; Kiss, B; Lasoń-Tyburkiewicz, M; Papp, M | 1 |
| Aguiar, DC; Almeida-Santos, AF; Duarte, ID; Ferreira, RC; Gobira, PH; Moreira, FA; Romero, TR; Souza, DP | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Abrial, E; Bétourné, A; Etiévant, A; Haddjeri, N; Lambás-Señas, L; Lucas, G; Scarna, H | 1 |
| Ahn, SM; Choi, BT; Hong, KH; Kim, HN; Kim, YR; Pak, ME; Shin, HK | 1 |
| Bent, S; Hendren, RL | 1 |
| Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG | 1 |
| Adham, N; Fone, KCF; Gyertyán, I; King, MV; Kiss, B; Watson, DJG | 1 |
| Giermaziak, W; Kus, K; Nowakowska, E; Ratajczak, P | 1 |
| Antoniów, M; Grześkowiak, E; Kus, K; Nowakowska, E; Ratajczak, P; Szkutnik-Fiedler, D | 1 |
| Bye, CR; Ganella, DE; Kim, JH; Lawrence, AJ; Madsen, HB; Perry, CJ; Zbukvic, IC | 1 |
| Bieńkowski, P; Jastrzębska-Więsek, M; Kołaczkowski, M; Mierzejewski, P; Partyka, A; Wasik, A; Wesołowska, A | 1 |
| Bondi, CO; Kline, AE; Mattiola, VV; Phelps, TI | 1 |
| Ashraf, NS; Cook, D; Costa, MDC; Dharia, RM; Dulchavsky, M; Fischer, S; Gestwicki, JE; Ivanova, MI; Joshi, G; Larsen, MJ; McQuade, TJ; Ouyang, M; Paulson, HL; Schapka, E; Sun, D; Todi, SV; Yang, Y | 1 |
| Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK | 1 |
| Bourin, M; Chenu, F; Hascoët, M; Prica, C | 1 |
| Avenet, P; Bergis, O; Boulay, D; Griebel, G | 1 |
| Mavrikaki, M; Nomikos, GG; Panagis, G | 1 |
| Hedlund, PB; Roberts, AJ; Sarkisyan, G | 1 |
| Biojone, C; Casarotto, PC; Guimarães, FS; Moreira, FA; Resstel, LB; Zangrossi, H | 1 |
| Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| De Carolis, L; Milella, MS; Nencini, P; Schepisi, C | 1 |
| Burda, K; Czubak, A; Kus, K; Nowakowska, E; Ratajczak, P; Zin, J | 1 |
| Ahlbrand, R; Bronson, SL; Grainger, M; Horn, P; McNamara, RK; Richtand, NM; Tambyraja, R | 1 |
| Chadman, KK; Guariglia, SR; Yoo, JH | 1 |
| Citraro, R; Davoli, A; De Sarro, G; Di Paola, ED; Gallelli, L; Russo, E | 1 |
| Aguiar, DC; Almeida-Santos, AF; Moreira, FA; Viana, TG | 1 |
| Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Altar, CA; Feltenstein, MW; See, RE | 1 |
| Koob, GF; Pulvirenti, L; Wang, Z; Wee, S; Woolverton, WL | 1 |
5 review(s) available for aripiprazole and Disease Models, Animal
| Article | Year |
|---|---|
Complementary and alternative treatments for autism part 1: evidence-supported treatments.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Complementary Therapies; Disease Models, Animal; Evidence-Based Medicine; Free Radical Scavengers; Gastrointestinal Tract; Humans; Inflammation; Mice; Oxidative Stress; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration; Vitamin B 12 | 2015 |
Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Chlorpromazine; Clozapine; Disease Models, Animal; Gene Expression Regulation; Glycolysis; Humans; Mitochondrial Proteins; Nerve Tissue Proteins; Oxidative Phosphorylation; Proteome; Proteomics; Schizophrenia; Treatment Outcome | 2016 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Child; Child Behavior; Child Development Disorders, Pervasive; Child, Preschool; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Discovery; GluK2 Kainate Receptor; Glutamic Acid; Humans; Methylphenidate; Mice; Mice, Inbred C57BL; Oxytocin; Piperazines; Quinolones; Rats; Receptors, Kainic Acid; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2012 |
Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Aripiprazole; Behavior, Animal; Cognition; Cognition Disorders; Depression; Disease Models, Animal; Epilepsy, Absence; Nootropic Agents; Piperazines; Quinolones; Rats; Rats, Inbred Strains | 2013 |
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
68 other study(ies) available for aripiprazole and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists.
Topics: Animals; Antipsychotic Agents; Benzazepines; Biological Assay; Disease Models, Animal; Dopamine Agonists; Drug Partial Agonism; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Rats; Receptors, Dopamine D2; Structure-Activity Relationship | 2013 |
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dogs; Half-Life; Humans; Inhibitory Concentration 50; Mice; Microsomes, Liver; Pyrimidinones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Structure-Activity Relationship | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Mice; Mice, Inbred ICR; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2021 |
Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aripiprazole; Brain; Disease Models, Animal; Female; Glucose; Hippocampus; Humans; Inflammation; Mice, Inbred C57BL; Mice, Transgenic | 2021 |
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior | 2022 |
Neuroprotective effects of aripiprazole in stress-induced depressive-like behavior: Possible role of CACNA1C.
Topics: Animals; Antidepressive Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcium Channels, L-Type; Depression; Disease Models, Animal; GAP-43 Protein; Hippocampus; Interleukin-6; Neuroprotective Agents; Rats; Stress, Psychological | 2022 |
The Sapap3
Topics: Animals; Aripiprazole; Comorbidity; Disease Models, Animal; Mice; Mice, Knockout; Nerve Tissue Proteins; Obsessive-Compulsive Disorder; Tics; Tourette Syndrome | 2023 |
Maternal treatment with aripiprazole prevents the development of a valproic acid-induced autism-like phenotype in juvenile male mice.
Topics: Animals; Anticonvulsants; Aripiprazole; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Female; Male; Mice; Phenotype; Pregnancy; Prenatal Exposure Delayed Effects; Seizures; Social Behavior; Valproic Acid | 2023 |
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Glutamates; Hippocampus; Homeostasis; Male; Memantine; Pregnancy; Rats; Rats, Wistar; Valproic Acid | 2023 |
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cognition; Disease Models, Animal; Female; Male; Methylazoxymethanol Acetate; Morris Water Maze Test; Neurotoxins; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Spatial Memory; Tobacco Smoke Pollution; Treatment Outcome | 2020 |
Role of the treatment environment in the effects of aripiprazole on ethanol-induced behavioral sensitization and conditioned place preference in female mice.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Aripiprazole; Behavior, Animal; Conditioning, Classical; Disease Models, Animal; Dopamine Agonists; Environment; Ethanol; Female; Mice | 2020 |
Aripiprazole and topiramate, alone or in combination, block the expression of ethanol-induced conditioned place preference in mice.
Topics: Animals; Aripiprazole; Behavior, Animal; Conditioning, Classical; Disease Models, Animal; Drug Combinations; Ethanol; Male; Mice; Topiramate | 2021 |
Topics: Administration, Intranasal; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Humans; Male; Mice; Motor Activity; Nanogels; Nanoparticle Drug Delivery System; Particle Size; Schizophrenia; Spectroscopy, Fourier Transform Infrared | 2021 |
Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escitalopram; Glutathione; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2021 |
Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Central Nervous System Depressants; Cognition Disorders; Disease Models, Animal; Drug Therapy, Combination; Ethanol; Female; Fluoxetine; Locomotion; Maze Learning; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Reaction Time; Time Factors | 2017 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Topics: Anhedonia; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Aripiprazole; Chronic Disease; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Imipramine; Male; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Receptors, Dopamine D3; Stress, Psychological; Uncertainty | 2017 |
Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Cytokines; Disease Models, Animal; Ghrelin; Glucagon-Like Peptide 1; Leptin; Male; Metabolic Syndrome; Poly I-C; Random Allocation; Rats, Wistar; Schizophrenia | 2017 |
Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal
Topics: Animals; Antipsychotic Agents; Aripiprazole; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Disease Models, Animal; Glutamic Acid; Magnetic Resonance Spectroscopy; Male; Motor Activity; Neuroprotective Agents; Rats; Rats, Inbred WKY; Riluzole | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopaminergic Neurons; Female; Haloperidol; Male; Mice; Mice, Inbred ICR; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects; Risperidone; Social Behavior; Valproic Acid | 2017 |
Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex.
Topics: Animals; Aripiprazole; Brain; Disease Models, Animal; Dopamine; Functional Laterality; Haloperidol; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Recovery of Function; Somatosensory Cortex; Stroke | 2018 |
Poly(I:C) model of schizophrenia in rats induces sex-dependent functional brain changes detected by MRI that are not reversed by aripiprazole treatment.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Cerebrovascular Circulation; Disease Models, Animal; Female; Magnetic Resonance Imaging; Male; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Rats, Wistar; Schizophrenia; Sex Characteristics | 2018 |
The influence of aripiprazole and venlafaxine on the antidepressant-like effect observed in prenatally stressed rats (animal model of depression).
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Depression; Disease Models, Animal; Drug Therapy, Combination; Female; Locomotion; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Wistar; Stress, Psychological; Swimming; Venlafaxine Hydrochloride | 2018 |
Omega-3 fatty acids supplementation with lithium and aripiprazole for improving the balance of circulating hormones and brain neurotransmitters in manic mice model.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Disease Models, Animal; Drug Therapy, Combination; Fatty Acids, Omega-3; Glycogen Synthase Kinase 3 beta; Hormones; Lithium Compounds; Male; Mice; Neurotransmitter Agents; Proto-Oncogene Proteins c-akt; RNA, Messenger | 2018 |
Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles.
Topics: Animals; Antidepressive Agents; Aripiprazole; Brain; Depressive Disorder, Treatment-Resistant; Desipramine; Disease Models, Animal; Dominance-Subordination; Dopamine; Drug Therapy, Combination; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Norepinephrine; Serotonin; Sertraline; Sexual Maturation; Social Behavior; Stress, Psychological | 2018 |
Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: Locomotor response, neuroimmunological profile and pharmacological modulation.
Topics: Animals; Antidepressive Agents; Aripiprazole; Bipolar Disorder; Brain; Cytokines; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Lithium; Locomotion; Male; Mice; Nerve Growth Factors; Piperazines; Time Factors; Valproic Acid | 2018 |
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Drug Therapy, Combination; Hyperkinesis; Male; Memory Disorders; Mianserin; Mice; Mirtazapine; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology | 2018 |
Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole.
Topics: Analgesics; Animals; Aripiprazole; Cannabinoid Receptor Agonists; Dinoprostone; Disease Models, Animal; Endocannabinoids; Hyperalgesia; Male; Mice; Nociceptive Pain; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Signal Transduction | 2019 |
State-dependent effects of the D
Topics: Animals; Apomorphine; Aripiprazole; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopaminergic Neurons; Electroencephalography; Haloperidol; Male; Methylazoxymethanol Acetate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Ventral Tegmental Area | 2019 |
Subchronic administration of aripiprazole improves fear extinction retrieval of Pavlovian conditioning paradigm in rats experiencing psychological trauma.
Topics: Amygdala; Animals; Aripiprazole; Conditioning, Classical; Disease Models, Animal; Extinction, Psychological; Fear; Male; Memory; Psychological Trauma; Rats, Sprague-Dawley; Stress Disorders, Post-Traumatic; Stress, Psychological | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Methylazoxymethanol Acetate; Mice; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Prepulse Inhibition; Risperidone; Schizophrenia | 2019 |
Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model.
Topics: Animals; Aripiprazole; Brain; Brain Ischemia; Carotid Stenosis; Cilostazol; Cognition; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; Drug Therapy, Combination; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Spatial Learning | 2019 |
Preventative effects of aripiprazole and quetiapine on seizure and lethality in a mice cocaine toxicity model: an experimental study.
Topics: Anesthetics, Local; Animals; Antipsychotic Agents; Aripiprazole; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Mice; Mice, Inbred BALB C; Quetiapine Fumarate; Seizures; Survival Rate | 2019 |
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.
Topics: Animals; Aripiprazole; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Models, Animal; Dopamine; Fluoxetine; Hippocampus; Male; Mice; Mice, Inbred C57BL; Nucleus Accumbens; Prefrontal Cortex; Serotonin; Signal Transduction; Stress, Psychological; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 2019 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome | 2013 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors | 2013 |
Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Blotting, Western; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Fragile X Mental Retardation Protein; Fragile X Syndrome; Immunoenzyme Techniques; Male; Mice; Mice, Knockout; Motor Activity; Muscarinic Antagonists; Piperazines; Pyridines; Quinolones; Receptor, Metabotropic Glutamate 5; Reward; Trihexyphenidyl; Tyrosine 3-Monooxygenase | 2013 |
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Topics: Adenosine A2 Receptor Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cebus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Motor Activity; Phosphodiesterase Inhibitors; Piperazines; Pyrazoles; Pyrimidines; Quinolines; Quinolones; Triazoles | 2014 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Male; Mice; Motor Activity; Piperazines; Quinolones; Thiazoles | 2014 |
Beneficial in vivo effect of aripiprazole on neuronal regeneration following neuronal loss in the dentate gyrus: evaluation using a mouse model of trimethyltin-induced neuronal loss/self-repair in the dentate gyrus.
Topics: Animals; Aripiprazole; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Cell Survival; Dentate Gyrus; Disease Models, Animal; Male; Mice; Mice, Inbred Strains; Nerve Regeneration; Nestin; Neural Stem Cells; Piperazines; Quinolones; Trimethyltin Compounds | 2014 |
Combination of omega-3 Fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania.
Topics: Animals; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Brain Chemistry; Disease Models, Animal; Fatty Acids, Omega-3; Glutathione; Lithium Compounds; Male; Mice; Oxidative Stress; Oxidoreductases; Piperazines; Quinolones | 2014 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Imipramine; Male; Piperazines; Quinolones; Rats, Wistar; Stress, Psychological | 2014 |
The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Conditioning, Psychological; Disease Models, Animal; Male; Mice; Morphine; Motor Activity; Nociception; Opioid-Related Disorders; Piperazines; Quinolones; Reward | 2014 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzophenanthridines; Bipolar Disorder; Cell Proliferation; Disease Models, Animal; Fluoxetine; Hippocampus; Lithium Chloride; Male; Piperazines; Prefrontal Cortex; Protein Kinase C; Protein Kinase Inhibitors; Quinolones; Rats, Sprague-Dawley; Sleep Deprivation; Tamoxifen | 2014 |
Studies on the animal model of post-stroke depression and application of antipsychotic aripiprazole.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain; Depression; Disease Models, Animal; Dopaminergic Neurons; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Stress, Psychological; Stroke | 2015 |
The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Association Learning; Developmental Disabilities; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Interpersonal Relations; Locomotion; Male; Memory Disorders; Phencyclidine; Piperazines; Rats; Recognition, Psychology; Schizophrenia | 2016 |
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Ethanol; Female; Male; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological | 2016 |
Coadministration of tramadol with aripiprazole and venlafaxine--The effect on spatial memory functions in male rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Chronic Pain; Depression; Disease Models, Animal; Male; Maze Learning; Memory Disorders; Rats; Rats, Wistar; Spatial Memory; Tramadol; Venlafaxine Hydrochloride | 2016 |
Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cocaine; Cocaine-Related Disorders; Cues; Disease Models, Animal; Dopamine Agonists; Dopamine Uptake Inhibitors; Extinction, Psychological; Learning; Male; Motivation; Prefrontal Cortex; Quinpirole; Random Allocation; Rats, Sprague-Dawley; Receptors, Dopamine D2; Self Administration | 2016 |
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Conditioning, Psychological; Conflict, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Isoxazoles; Male; Maze Learning; Mice; Motor Activity; Olanzapine; Punishment; Rats, Wistar; Reaction Time; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Sulfonamides | 2016 |
Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain Injuries, Traumatic; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hippocampus; Male; Maze Learning; Motor Activity; Neurons; Random Allocation; Rats, Sprague-Dawley; Recovery of Function; Spatial Memory | 2017 |
Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Aripiprazole; Ataxin-3; Brain; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Gene Expression Regulation; HEK293 Cells; Humans; Machado-Joseph Disease; Mice; Mutant Proteins; Nerve Tissue Proteins; Organ Culture Techniques; Peptides; Piperidines; Pyrans; Pyrazoles | 2016 |
Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke.
Topics: Animals; Antidepressive Agents; Aripiprazole; Atrophy; Behavior, Animal; Brain; Cell Differentiation; Cell Proliferation; Cilostazol; CREB-Binding Protein; Depression; Disease Models, Animal; Drug Synergism; Male; Mice; Neural Stem Cells; Phenotype; Phosphorylation; Stress, Psychological; Stroke; Tetrazoles | 2017 |
Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Synergism; Drug Therapy, Combination; Male; Mice; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Stress, Psychological | 2009 |
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Dopamine Plasma Membrane Transport Proteins; Glycine Plasma Membrane Transport Proteins; Hyperkinesis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Piperazines; Quinolones; Receptors, N-Methyl-D-Aspartate | 2010 |
Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Central Nervous System Stimulants; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Locomotion; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Self Stimulation | 2010 |
The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Corticosterone; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Hindlimb Suspension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Phenols; Piperazines; Quinolones; Receptors, Serotonin; Serotonin Antagonists; Sulfonamides; Swimming | 2010 |
Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Male; Maze Learning; Motor Activity; Piperazines; Quinolones; Rats; Rats, Wistar | 2011 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Behavioral Symptoms; Disease Models, Animal; Dizocilpine Maleate; Haloperidol; In Situ Nick-End Labeling; Inhibition, Psychological; Male; Methamphetamine; Microdialysis; Motor Activity; Neuroprotective Agents; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 2011 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Clomipramine; Compulsive Behavior; Conditioning, Operant; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drinking Behavior; Haloperidol; Male; Piperazines; Quinolones; Quinpirole; Rats; Rats, Sprague-Dawley | 2011 |
Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.
Topics: Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Cognition; Depression; Disease Models, Animal; Male; Maze Learning; Memory; Piperazines; Quinolones; Rats; Rats, Wistar; Toxicity Tests | 2011 |
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoxetine; Immune System; Male; Motor Activity; Piperazines; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2012 |
Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Exploratory Behavior; Male; Mice; Motor Activity; Motor Neurons; Piperazines; Postural Balance; Quinolones; Rotarod Performance Test | 2013 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Extinction, Psychological; Male; Motor Activity; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Secondary Prevention; Self Administration | 2007 |
Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Aripiprazole; Brain; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Drug Interactions; Male; Methamphetamine; Nucleus Accumbens; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Self Administration | 2007 |